<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015144</url>
  </required_header>
  <id_info>
    <org_study_id>502-11-585</org_study_id>
    <nct_id>NCT01015144</nct_id>
  </id_info>
  <brief_title>The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle</brief_title>
  <official_title>The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle in Patients With Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Lodz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to assess of the influence of atorvastatin on selected indicators of&#xD;
      an inflammatory condition, function of the left ventricle and factors affecting the&#xD;
      occurrence of undesired events like rehospitalizations and mortality in patients with dilated&#xD;
      cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricular function</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>No statin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tulip</intervention_name>
    <description>Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood68&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with dilated cardiomyopathy (according ESC 2007) with EF≤40% as documented by&#xD;
        echocardiography were included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients 18 years old or older&#xD;
&#xD;
          -  patients who signed informed consent&#xD;
&#xD;
          -  patients with dilated cardiomyopathy (according ESC 2007)&#xD;
&#xD;
          -  patients who had no significant coronary artery stenoses &gt;30% on cardiac&#xD;
             catheterization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BP ≥140/90 lub &lt;90/60&#xD;
&#xD;
          -  congenital heart disease&#xD;
&#xD;
          -  acquired valvular disease except for mitral incompetence secondary to left ventricular&#xD;
             dilatation&#xD;
&#xD;
          -  New York Heart Association (NYHA) functional class IV&#xD;
&#xD;
          -  statin treatment&#xD;
&#xD;
          -  preserved hyperactivity of aminotransferases with unexplained etiology,&#xD;
&#xD;
          -  muscle disorders which might cause drug-induced myopathy,&#xD;
&#xD;
          -  uncontrolled diabetes,&#xD;
&#xD;
          -  liver diseases,&#xD;
&#xD;
          -  creatinine level &gt; 2 mg/dl and/or GFR&lt;30ml/min,&#xD;
&#xD;
          -  abuse of alcohol or drugs,&#xD;
&#xD;
          -  chronic inflammatory diseases,&#xD;
&#xD;
          -  pregnancy or lactation,&#xD;
&#xD;
          -  severe hypothyroidism,&#xD;
&#xD;
          -  immunosuppressive treatment,&#xD;
&#xD;
          -  operation or severe injury during last month&#xD;
&#xD;
          -  vaccination during last 3 months&#xD;
&#xD;
          -  heart stimulation device or implantable cardioverter defibrillator&#xD;
&#xD;
          -  or who didn't write conscious consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agata Bielecka-Dabrowa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hypertension UM Lodz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maciej Banach, Assoc. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Hypertension UM Lodz</affiliation>
  </overall_official>
  <reference>
    <citation>Bielecka-Dabrowa A, Wierzbicka M, Dabrowa M, Goch A. New methods in laboratory diagnostics of dilated cardiomyopathy. Cardiol J. 2008;15(4):388-95. Review.</citation>
    <PMID>18698552</PMID>
  </reference>
  <reference>
    <citation>Bielecka-Dabrowa A, Wierzbicka M, Goch JH. [Proinflammatory cytokines in cardiovascular diseases as potential therapeutic target]. Wiad Lek. 2007;60(9-10):433-8. Review. Polish.</citation>
    <PMID>18350717</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>November 17, 2009</last_update_submitted>
  <last_update_submitted_qc>November 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Agata Bielecka-Dąbrowa</name_title>
    <organization>UM Lodz</organization>
  </responsible_party>
  <keyword>atorvastatin</keyword>
  <keyword>dilated cardiomyopathy</keyword>
  <keyword>heart failure</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

